Regerd 40 mg/vial (IV Injection)

40 mg vial: ৳ 85.00

Medicine Details

Category	Details
Generic	Omeprazole
Company	Novatek pharmaceuticals ltd
Also available as	Regerd 20 mg capsule Regerd 40 mg capsule

Indications

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Pharmacology

Omeprazole, a substituted benzimidazole, is an inhibitor of gastric acid secretion. It inhibits gastric acid secretion by blocking hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system in the gastric parietal cell. After oral administration, the onset of the antisecretory effect occurs within one hour, with the maximum effect occurring within two hours and inhibition of secretion lasts up to 72 hours. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days.

Dosage

Benign gastric and duodenal ulcer: 20 mg once daily for 4 weeks in duodenal ulceration, 8 weeks in gastric ulceration
NSAID-associated duodenal or gastric ulcer: 20 mg once daily for 4 weeks
Gastro-esophageal reflux disease: 20 mg once daily for 4 weeks, continued for further 4-8 weeks
Long-term management of acid reflux disease: 10-20 mg daily
Acid-related dyspepsia: 10-20 mg once daily for 2-4 weeks
Prophylaxis of acid aspiration: 40 mg on the preceding evening, then 40 mg 2-6 hours before surgery
Zollinger-Ellison syndrome: Initially 60 mg once daily
Helicobacter pylori eradication regimen in peptic ulcer disease: Omeprazole is recommended at a dose of 20 mg twice daily in association with antimicrobial agents

Administration

Omeprazole IV injection should be given as a slow intravenous injection. The solution for IV injection is obtained by adding 10 ml water for injection to the vial containing powder. After reconstitution, the injection should be given slowly over a period of at least 2 to 5 minutes at a maximum rate of 4 ml/minute.

Interaction

Absorption of ketoconazole may be reduced during Regerd treatment. Regerd is metabolized in the liver through cytochrome P450 and can delay the elimination of diazepam, phenytoin, and warfarin. Plasma concentrations of Regerd and clarithromycin are increased during concomitant administration.

Contraindications

Omeprazole is contraindicated in patients with known hypersensitivity to it. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with omeprazole is instituted.

Side Effects

Adverse reactions have generally been mild and reversible, including skin rash, urticaria, pruritus, photosensitivity, bullous eruption, diarrhea, headache, constipation, nausea/vomiting, and more.

Pregnancy & Lactation

Results from three prospective epidemiological studies indicate no adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child. Omeprazole can be used during pregnancy. There is no information available on the passage of Omeprazole into breast milk or its effects on the neonate. Breast-feeding should, therefore, be discontinued if the use of Omeprazole is considered essential.

Precautions & Warnings

Avoid concomitant use of clopidogrel and Regerd as the pharmacological activity of clopidogrel is reduced if given concomitantly. Observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine.